TY - JOUR
T1 - Molecular landscape of recurrent cervical cancer
AU - Adiga, Divya
AU - Eswaran, Sangavi
AU - Pandey, Deeksha
AU - Sharan, Krishna
AU - Kabekkodu, Shama Prasada
N1 - Funding Information:
We thank Department of Science and Technology (DST), Government of India (Grant No: EMR/2016/002314 ), Science and Engineering Research Board (SERB) , Department of Biotechnology (DBT), Government of India ( 6242-P8/RGCB/PMD/DBT/SPDK/2015 ), ICMR-Senior Research fellowship, Government of India (Reference ID- 2019/4115/CMB/BMS) and DST-Ph.D. fellowship, KSTepS, Department of Science and Technology (DST), Government of Karnataka (Reference ID- DST/KSTePS/Ph.D. Fellowship/LIF-11: 2019-20) for financial assistance. We thank Manipal Academy of Higher education, Manipal for infrastructure support.
Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Cervical cancer (CC) is a major gynecological problem in developing and underdeveloped countries. Despite the significant advancement in early detection and treatment modalities, several patients recur. Moreover, the molecular mechanisms responsible for CC recurrence remains obscure. The patients with CC recurrence often show poor prognosis and significantly high mortality rates. The clinical management of recurrent CC depends on treatment history, site, and extent of the recurrence. Owing to poor prognosis and limited treatment options, recurrent CC often presents a challenge to the clinicians. Several in vitro, in vivo, and patient studies have led to the identification of the critical molecular changes responsible for CC recurrence. Both aberrant genetic and epigenetic modifications leading to altered cell signaling pathways have been reported to impact CC recurrence. Researchers are currently trying to dissect the molecular pathways in CC and translate these findings for better management of disease. This article attempts to review the existing knowledge of disease relapse, accompanying challenges, and associated molecular players in CC.
AB - Cervical cancer (CC) is a major gynecological problem in developing and underdeveloped countries. Despite the significant advancement in early detection and treatment modalities, several patients recur. Moreover, the molecular mechanisms responsible for CC recurrence remains obscure. The patients with CC recurrence often show poor prognosis and significantly high mortality rates. The clinical management of recurrent CC depends on treatment history, site, and extent of the recurrence. Owing to poor prognosis and limited treatment options, recurrent CC often presents a challenge to the clinicians. Several in vitro, in vivo, and patient studies have led to the identification of the critical molecular changes responsible for CC recurrence. Both aberrant genetic and epigenetic modifications leading to altered cell signaling pathways have been reported to impact CC recurrence. Researchers are currently trying to dissect the molecular pathways in CC and translate these findings for better management of disease. This article attempts to review the existing knowledge of disease relapse, accompanying challenges, and associated molecular players in CC.
UR - http://www.scopus.com/inward/record.url?scp=85097092236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097092236&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2020.103178
DO - 10.1016/j.critrevonc.2020.103178
M3 - Review article
AN - SCOPUS:85097092236
SN - 1040-8428
VL - 157
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103178
ER -